BERKELEY, Calif. and VANCOUVER, British Columbia, Feb. 07, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp.
("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary
targeted immunotherapy technology, announced that it will be attending BIO CEO & Investor Conference 2018. The conference will be
held February 12-13, 2018 at New York Marriott Marquis Hotel (1535 Broadway, New York, NY 10036). Dr. Saeid Babaei, BriaCell’s
Chairman of the Board, and Dr. Bill Williams, BriaCell’s President & CEO, will be available for one-on-one meetings from February
12 to February 13, 2018 in New York.
To arrange a one-on-one meeting with the Company during the event, please contact:
Farrah Dean
Manager, Corporate Development
Email: farrah@BriaCell.com
Phone: 1-888-485-6340
An updated presentation will be available for download at http://briacell.com/investor-relations/presentations/.
About the 2018 BIO CEO & Investor Conference
In its 20th year, the BIO CEO & Investor Conference, where biotech's elite engage the Street, is one
of the largest investor conferences focused on publicly traded and select private biotech companies. The conference mission is to
support industry-wide success by presenting a broad and unbiased view of investment opportunities.
The conference provides a neutral forum where institutional investors, industry analysts, and senior
biotechnology executives gather to shape the future investment landscape of the biotechnology industry. The conference showcases
issue-oriented plenary sessions, educational sessions focused on key therapeutic areas, business issues, company presentations,
one-on-one meetings, and networking opportunities.
The therapeutic workshops present medical doctors, chief scientific officers and industry analysts discuss the
latest information on pipeline innovation for breakthrough therapeutic topics in biopharma. Seasoned industry executives and
analysts discuss timely and relevant business models, deal-making and investment trends on the business roundtables.
For more information on the BIO CEO & Investor Conference 2018, please visit
https://www.bio.org/events/bio-ceo-investor-conference.
About BriaCell
BriaCell is an immuno-oncology focused biotechnology company developing a targeted and safe approach to the
management of cancer. Immunotherapy has come to the forefront in the fight against cancer, harnessing the body's own immune system
in recognizing and selectively destroying cancer cells while sparing normal ones. Immunotherapy, in addition to generally being
more targeted and less toxic than commonly used types of chemotherapy, is also thought to be a potent approach with the potential
to prevent cancer recurrence.
Bria-IMT™ (SV-BR-1-GM), the Company's lead product candidate, is derived from a specific breast cancer cell
line. It is genetically engineered to release granulocyte-macrophage colony-stimulating factor (GM-CSF), a substance that activates
the immune system. We believe that Bria-IMT™ helps the body to recognize and kill tumor cells by activating T cells that attack the
tumor and B cells that produce anti-tumor antibodies.
The results of two previous proof-of-concept clinical trials (one with the precursor cell line not genetically
engineered to produce GM-CSF and one with Bria-IMT™) produced encouraging results in patients with advanced breast cancer. Most
notably, one patient with metastatic breast cancer responded to Bria-IMT™ with substantial reduction in tumor burden including
breast, lung, soft tissue and brain metastases. The company is currently conducting a Phase I/IIa clinical trial for Bria-IMT™ in
patients with advanced breast cancer. This trial is listed in ClinicalTrials.gov as NCT03066947. The trial is being conducted along
with the co-development of BriaDX™, the Company’s companion diagnostic test. The interim data for the first 10 patients is expected
by the first quarter of 2018. Additionally, the FDA recently approved the roll-over combination study of Bria-IMT™ with
pembrolizumab [Keytruda®; manufactured by Merck & Co., Inc.] or ipilimumab [Yervoy®; manufactured by Bristol-Myers Squibb Company]
for patients previously treated with Bria-IMT™ in the Company’s ongoing Phase I/IIa clinical trial in advanced breast cancer. The
roll-over trial is listed in ClinicalTrials.gov as NCT03328026.
BriaCell is also developing Bria-OTS™, an off-the-shelf personalized Immunotherapy. Bria-OTS™ consists of 14
individually pre-manufactured genetic alleles. BriaCell’s BriaDX™ companion diagnostic reveals a patient’s specific HLA-types and
the 2 best matching alleles are administered to the patient. BriaCell’s 14 alleles (8 Class I and 6 Class II) cover approximately
90% of the Breast Cancer population while eliminating the complex manufacturing logistics required for other personalized
immunotherapies. Bria-OTS™ is a personalized therapy without the need for personalized manufacturing.
Yet another item in the BriaCell pipeline is a novel, selective protein kinase C delta (PKCδ) inhibitor. PKCδ
inhibitors have shown activity in a number of pre-clinical models of RAS genes’ transformed cancers including breast, pancreatic,
non-small cell lung cancer and neuroendocrine tumors (such as carcinoid tumors).
For additional information on BriaCell, please visit our website: http://briacell.com.
Cautionary Note Regarding Forward-Looking Information
Except for the statements of historical fact, this news release contains "forward-looking information" within
the meaning of the applicable Canadian securities legislation which involves known and unknown risks relevant to the Company in
particular and to the biotechnology and pharmaceutical industries in general, uncertainties and other factors that may cause actual
events to differ materially from current expectation. These risks are more fully described in the Company's public filings
available at www.sedar.com.
Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of
the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update
or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact Information
For further information, please contact:
BriaCell Therapeutics Corp.:
Farrah Dean
Manager, Corporate Development
Email: farrah@BriaCell.com
Phone: 1-888-485-6340
